REVIEW ARTICLE
Protein O-GlcNAcylation in the heart
Yann Huey Ng,
Chidinma A. Okolo,
Jeffrey R. Erickson,
James C. Baldi,
Peter P. Jones,
Yann Huey Ng
Department of Medicine and HeartOtago, University of Otago, Dunedin, New Zealand
Search for more papers by this authorChidinma A. Okolo
Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
Life Sciences Division, Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, UK
Search for more papers by this authorJeffrey R. Erickson
Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
Search for more papers by this authorJames C. Baldi
Department of Medicine and HeartOtago, University of Otago, Dunedin, New Zealand
Search for more papers by this authorCorresponding Author
Peter P. Jones
Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
Correspondence
Peter P. Jones, Department of Physiology and HeartOtago, School of Biomedical Sciences, University of Otago, 270 Great King Street, Dunedin Central, Dunedin 9016, New Zealand.
Email: [email protected]
Search for more papers by this author
Yann Huey Ng,
Chidinma A. Okolo,
Jeffrey R. Erickson,
James C. Baldi,
Peter P. Jones,
Yann Huey Ng
Department of Medicine and HeartOtago, University of Otago, Dunedin, New Zealand
Search for more papers by this authorChidinma A. Okolo
Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
Life Sciences Division, Diamond Light Source Ltd, Harwell Science and Innovation Campus, Didcot, UK
Search for more papers by this authorJeffrey R. Erickson
Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
Search for more papers by this authorJames C. Baldi
Department of Medicine and HeartOtago, University of Otago, Dunedin, New Zealand
Search for more papers by this authorCorresponding Author
Peter P. Jones
Department of Physiology and HeartOtago, University of Otago, Dunedin, New Zealand
Correspondence
Peter P. Jones, Department of Physiology and HeartOtago, School of Biomedical Sciences, University of Otago, 270 Great King Street, Dunedin Central, Dunedin 9016, New Zealand.
Email: [email protected]
Search for more papers by this authorYann Huey Ng and Chidinma A. Okolo contributed equally to this manuscript.
Abstract
O-GlcNAcylation is a ubiquitous post-translational modification that is extremely labile and plays a significant role in physiology, including the heart. Sustained activation of cardiac O-GlcNAcylation is frequently associated with alterations in cellular metabolism, leading to detrimental effects on cardiovascular function. This is particularly true during conditions such as diabetes, hypertension, cardiac remodelling, heart failure and arrhythmogenesis. Paradoxically, transient elevation of cardiac protein O-GlcNAcylation can also exert beneficial effects in the heart. There is compelling evidence to suggest that a complex interaction between O-GlcNAcylation and phosphorylation also exists in the heart. Beyond direct functional consequences on cardiomyocytes, O-GlcNAcylation also acts indirectly by altering the function of transcription factors that affect downstream signalling. This review focuses on the potential cardioprotective role of protein O-GlcNAcylation during ischaemia-reperfusion injury, the deleterious consequences of chronically elevated O-GlcNAc levels, the interplay between O-GlcNAcylation and phosphorylation in the cardiomyocytes and the effects of O-GlcNAcylation on other major non-myocyte cell types in the heart.
CONFLICT OF INTEREST
The authors have declared no conflict of interest.
REFERENCES
- 1Zachara NE, O'Donnell N, Cheung WD, Mercer JJ, Marth JD, Hart GW. Dynamic O-GlcNAc modification of nucleocytoplasmic proteins in response to stress. A survival response of mammalian cells. J Biol Chem. 2004; 279(29): 30133-30142.
- 2Roquemore EP, Dell A, Morris HR, et al. Vertebrate lens alpha-crystallins are modified by O-linked N-acetylglucosamine. J Biol Chem. 1992; 267(1): 555-563.
- 3Roquemore EP, Chevrier MR, Cotter RJ, Hart GW. Dynamic O-GlcNAcylation of the small heat shock protein αB-crystallin. Biochemistry. 1996; 35(11): 3578-3586.
- 4Bourré G, Cantrelle F-X, Kamah A, Chambraud B, Landrieu I, Smet-Nocca C. Direct crosstalk between O-GlcNAcylation and phosphorylation of tau protein investigated by NMR spectroscopy. Front Endocrinol (Lausanne). 2018; 9: 595.
- 5Wang S, Huang X, Sun D, et al. Extensive crosstalk between O-GlcNAcylation and phosphorylation regulates Akt signaling. PLoS One. 2012; 7(5):e37427.
- 6Wang Z, Gucek M, Hart GW. Cross-talk between GlcNAcylation and phosphorylation: site-specific phosphorylation dynamics in response to globally elevated O-GlcNAc. Proc Natl Acad Sci USA. 2008; 105(37): 13793-13798.
- 7Champattanachai V, Marchase RB, Chatham JC. Glucosamine protects neonatal cardiomyocytes from ischemia-reperfusion injury via increased protein-associated O-GlcNAc. Am J Physiol Cell Physiol. 2007; 292(1): C178-C187.
- 8Jensen RV, Johnsen J, Kristiansen SB, Zachara NE, Bøtker HE. Ischemic preconditioning increases myocardial O-GlcNAc glycosylation. Scand Cardiovasc J. 2013; 47(3): 168-174
- 9Ngoh GA, Hamid T, Prabhu SD, Jones SP. O-GlcNAc signaling attenuates ER stress-induced cardiomyocyte death. Am J Physiol Heart Circ Physiol. 2009; 297(5): H1711-H1719.
- 10Fülöp N, Mason MM, Dutta K, et al. Impact of type 2 diabetes and aging on cardiomyocyte function and O-linked N-acetylglucosamine levels in the heart. Am J Physiol Cell Physiol. 2007; 292(4): C1370-C1378.
- 11Erickson JR, Pereira L, Wang L, et al. Diabetic hyperglycaemia activates CaMKII and arrhythmias by O-linked glycosylation. Nature. 2013; 502(7471): 372-376.
- 12Dias WB, Cheung WD, Wang Z, Hart GW. Regulation of calcium/calmodulin-dependent kinase IV by O-GlcNAc modification. J Biol Chem. 2009; 284(32): 21327-21337.
- 13Olson AK, Bouchard B, Zhu WZ, Chatham JC, Des Rosiers C. First characterization of glucose flux through the hexosamine biosynthesis pathway (HBP) in ex vivo mouse heart. J Biol Chem. 2020; 295(7): 2018-2033.
- 14Marshall S, Bacote V, Traxinger RR. Complete inhibition of glucose-induced desensitization of the glucose transport system by inhibitors of mRNA synthesis. Evidence for rapid turnover of glutamine: fructose-6-phosphate amidotransferase. J Biol Chem. 1991; 266(16): 10155-10161.
- 15Marshall S, Bacote V, Traxinger RR. Discovery of a metabolic pathway mediating glucose-induced desensitization of the glucose transport system. Role of hexosamine biosynthesis in the induction of insulin resistance. J Biol Chem. 1991; 266(8): 4706-4712.
- 16Greig KT, Antonchuk J, Metcalf D, et al. Agm1/Pgm3-mediated sugar nucleotide synthesis is essential for hematopoiesis and development. Mol Cell Biol. 2007; 27(16): 5849-5859.
- 17Vocadlo DJ, Hang HC, Kim E-J, Hanover JA, Bertozzi CR. A chemical approach for identifying O-GlcNAc-modified proteins in cells. Proc Natl Acad Sci USA. 2003; 100(16): 9116-9121.
- 18Marshall S, Garvey WT, Traxinger RR. New insights into the metabolic regulation of insulin action and insulin resistance: role of glucose and amino acids. FASEB J. 1991; 5(15): 3031-3036.
- 19Spiro RG. Studies on the biosynthesis of glucosamine in the intact rat. J Biol Chem. 1959; 234(4): 742-748.
- 20Laczy B, Fülöp N, Onay-Besikci A, Des Rosiers C, Chatham JC. Acute regulation of cardiac metabolism by the hexosamine biosynthesis pathway and protein O-GlcNAcylation. PLoS One. 2011; 6(4):e18417.
- 21Rajamani U, Essop MF. Hyperglycemia-mediated activation of the hexosamine biosynthetic pathway results in myocardial apoptosis. Am J Physiol Cell Physiol. 2010; 299(1): C139-C147.
- 22Medford HM, Chatham JC, Marsh SA. Chronic ingestion of a Western diet increases O-linked-β-N-acetylglucosamine (O-GlcNAc) protein modification in the rat heart. Life Sci. 2012; 90(23): 883-888.
- 23Haltiwanger RS, Holt GD, Hart GW. Enzymatic addition of O-GlcNAc to nuclear and cytoplasmic proteins. Identification of a uridine diphospho-N-acetylglucosamine:peptide beta-N-acetylglucosaminyltransferase. J Biol Chem. 1990; 265(5): 2563-2568.
- 24Ramirez-Correa GA, Ma J, Slawson C, et al. Removal of abnormal myofilament O-GlcNAcylation restores Ca2+ sensitivity in diabetic cardiac muscle. Diabetes. 2015; 64(10): 3573-3587.
- 25Ngoh GA, Watson LJ, Facundo HT, Dillmann W, Jones SP. Non-canonical glycosyltransferase modulates post-hypoxic cardiac myocyte death and mitochondrial permeability transition. J Mol Cell Cardiol. 2008; 45(2): 313-325.
- 26Laczy B, Marsh SA, Brocks CA, Wittmann I, Chatham JC. Inhibition of O-GlcNAcase in perfused rat hearts by NAG-thiazolines at the time of reperfusion is cardioprotective in an O-GlcNAc-dependent manner. Am J Physiol Heart Circ Physiol. 2010; 299(5): H1715-H1727.
- 27Umapathi P, Banerjee PS, Zachara NE, et al. Excessive O-GlcNAcylation causes heart failure and sudden death. Circulation. 2021; 143(17): 1687-1703.
- 28Hubert HB, Feinleib M, McNamara PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Circulation. 1983; 67(5): 968-977.
- 29Horwich TB, Fonarow GC, Hamilton MA, MacLellan WR, Woo MA, Tillisch JH. The relationship between obesity and mortality in patients with heart failure. J Am Coll Cardiol. 2001; 38(3): 789-795.
- 30Oreopoulos A, Padwal R, Kalantar-Zadeh K, Fonarow GC, Norris CM, McAlister FA. Body mass index and mortality in heart failure: a meta-analysis. Am Heart J. 2008; 156(1): 13-22.
- 31Uretsky S, Messerli FH, Bangalore S, et al. Obesity paradox in patients with hypertension and coronary artery disease. Am J Med. 2007; 120(10): 863-870.
- 32Wu T, Zhou H, Jin Z, et al. Cardioprotection of salidroside from ischemia/reperfusion injury by increasing N-acetylglucosamine linkage to cellular proteins. Eur J Pharmacol. 2009; 613(1–3): 93-99.
- 33Liu J, Marchase RB, Chatham JC. Increased O-GlcNAc levels during reperfusion lead to improved functional recovery and reduced calpain proteolysis. Am J Physiol Heart Circ Physiol. 2007; 293(3): H1391-H1399.
- 34Liu J, Pang Y, Chang T, Bounelis P, Chatham JC, Marchase RB. Increased hexosamine biosynthesis and protein O-GlcNAc levels associated with myocardial protection against calcium paradox and ischemia. J Mol Cell Cardiol. 2006; 40(2): 303-312.
- 35Liu J, Marchase RB, Chatham JC. Glutamine-induced protection of isolated rat heart from ischemia/reperfusion injury is mediated via the hexosamine biosynthesis pathway and increased protein O-GlcNAc levels. J Mol Cell Cardiol. 2007; 42(1): 177-185.
- 36Veighey K, Macallister RJ. Clinical applications of remote ischemic preconditioning. Cardiol Res Pract. 2012; 2012: 1-9.
10.1155/2012/620681 Google Scholar
- 37Jones SP, Zachara NE, Ngoh GA, et al. Cardioprotection by N-acetylglucosamine linkage to cellular proteins. Circulation. 2008; 117(9): 1172.
- 38Kristiansen SB, Paelestik KB, Johnsen J, et al. Impact of hyperglycemia on myocardial ischemia-reperfusion susceptibility and ischemic preconditioning in hearts from rats with type 2 diabetes. Cardiovasc Diabetol. 2019; 18(1): 66.
- 39Paelestik KB, Jespersen NR, Jensen RV, Johnsen J, Botker HE, Kristiansen SB. Effects of hypoglycemia on myocardial susceptibility to ischemia-reperfusion injury and preconditioning in hearts from rats with and without type 2 diabetes. Cardiovasc Diabetol. 2017; 16(1): 148.
- 40Jensen RV, Zachara NE, Nielsen PH, Kimose HH, Kristiansen SB, Bøtker HE. Impact of O-GlcNAc on cardioprotection by remote ischaemic preconditioning in non-diabetic and diabetic patients. Cardiovasc Res. 2012; 97(2): 369-378.
- 41Rao RV, Ellerby HM, Bredesen DE. Coupling endoplasmic reticulum stress to the cell death program. Cell Death Differ. 2004; 11(4): 372-380.
- 42Xu C, Bailly-Maitre B, Reed JC. Endoplasmic reticulum stress: cell life and death decisions. J Clin Invest. 2005; 115(10): 2656-2664.
- 43Ngoh Gladys A, Facundo Heberty T, Hamid T, Dillmann W, Zachara Natasha E, Jones SP. Unique hexosaminidase reduces metabolic survival signal and sensitizes cardiac myocytes to hypoxia/reoxygenation injury. Circ Res. 2009; 104(1): 41-49.
- 44Zafir A, Readnower R, Long BW, et al. Protein O-GlcNAcylation is a novel cytoprotective signal in cardiac stem cells. Stem Cells. 2013; 31(4): 765-775.
- 45Marzo I, Brenner C, Zamzami N, et al. The permeability transition pore complex: a target for apoptosis regulation by caspases and bcl-2–related proteins. J Exp Med. 1998; 187(8): 1261-1271.
- 46Shoshan-Barmatz V, De Pinto V, Zweckstetter M, Raviv Z, Keinan N, Arbel N. VDAC, a multi-functional mitochondrial protein regulating cell life and death. Mol Aspects Med. 2010; 31(3): 227-285.
- 47Suh DH, Kim M-K, Kim HS, Chung HH, Song YS. Mitochondrial permeability transition pore as a selective target for anti-cancer therapy. Front Oncol. 2013; 3:41.
- 48Ma J, Liu T, Wei AC, Banerjee P, O'Rourke B, Hart GW. O-GlcNAcomic profiling identifies widespread O-linked beta-N-acetylglucosamine modification (O-GlcNAcylation) in oxidative phosphorylation system regulating cardiac mitochondrial function. J Biol Chem. 2015; 290(49): 29141-29153.
- 49Hirose K, Tsutsumi YM, Tsutsumi R, et al. Role of the O-linked beta-N-acetylglucosamine in the cardioprotection induced by isoflurane. Anesthesiology. 2011; 115(5): 955-962.
- 50Prakoso D, Lim SY, Erickson JR, et al. Fine-tuning the cardiac O-GlcNAcylation regulatory enzymes governs the functional and structural phenotype of the diabetic heart. Cardiovasc Res. 2021. https://doi.org/10.1093/cvr/cvab043
- 51Hu Y, Belke D, Suarez J, et al. Adenovirus-mediated overexpression of O-GlcNAcase improves contractile function in the diabetic heart. Circ Res. 2005; 96(9): 1006-1013.
- 52Lunde IG, Aronsen JM, Kvaløy H, et al. Cardiac O-GlcNAc signaling is increased in hypertrophy and heart failure. Physiol Genomics. 2011; 44(2): 162-172.
- 53Facundo HT, Brainard RE, Watson LJ, et al. O-GlcNAc signaling is essential for NFAT-mediated transcriptional reprogramming during cardiomyocyte hypertrophy. Am J Physiol Heart Circ Physiol. 2012; 302(10): H2122-H2130.
- 54Yu P, Hu L, Xie J, et al. O-GlcNAcylation of cardiac Nav1.5 contributes to the development of arrhythmias in diabetic hearts. Int J Cardiol. 2018; 260: 74-81.
- 55Xiao Z, Guo W, Sun B, et al. Enhanced cytosolic Ca2+ activation underlies a common defect of central domain cardiac ryanodine receptor mutations linked to arrhythmias. J Biol Chem. 2016; 291(47): 24528-24537.
- 56Zhang JZ, McLay JC, Jones PP. The arrhythmogenic human HRC point mutation S96A leads to spontaneous Ca(2+) release due to an impaired ability to buffer store Ca(2+). J Mol Cell Cardiol. 2014; 74: 22-31.
- 57Vogelstein B, Lane D, Levine AJ. Surfing the p53 network. Nature. 2000; 408(6810): 307-310.
- 58Gogiraju R, Xu X, Bochenek ML, et al. Endothelial p53 deletion improves angiogenesis and prevents cardiac fibrosis and heart failure induced by pressure overload in mice. J Am Heart Assoc. 2015; 4(2):e001770.
- 59Fiordaliso F, Leri A, Cesselli D, et al. Hyperglycemia activates p53 and p53-regulated genes leading to myocyte cell death. Diabetes. 2001; 50(10): 2363-2375.
- 60Guo X, Shang J, Deng Y, Yuan X, Zhu D, Liu H. Alterations in left ventricular function during intermittent hypoxia: possible involvement of O-GlcNAc protein and MAPK signaling. Int J Mol Med. 2015; 36(1): 150-158.
- 61Sanchez-Prieto R, Rojas JM, Taya Y, Gutkind JS. A role for the p38 mitogen-activated protein kinase pathway in the transcriptional activation of p53 on genotoxic stress by chemotherapeutic agents. Cancer Res. 2000; 60(9): 2464-2472.
- 62Bers DM. Cardiac excitation–contraction coupling. Nature. 2002; 415(6868): 198-205.
- 63Zahradnikova A, Zahradnik I, Gyorke I, Gyorke S. Rapid activation of the cardiac ryanodine receptor by submillisecond calcium stimuli. J Gen Physiol. 1999; 114(6): 787-798.
- 64Clark RJ, McDonough PM, Swanson E, et al. Diabetes and the accompanying hyperglycemia impairs cardiomyocyte calcium cycling through increased nuclear O-GlcNAcylation. J Biol Chem. 2003; 278(45): 44230-44237.
- 65Dutta K, Carmody MW, Cala SE, Davidoff AJ. Depressed PKA activity contributes to impaired SERCA function and is linked to the pathogenesis of glucose-induced cardiomyopathy. J Mol Cell Cardiol. 2002; 34(8): 985-996.
- 66Ren J, Gintant GA, Miller RE, Davidoff AJ. High extracellular glucose impairs cardiac E-C coupling in a glycosylation-dependent manner. Am J Physiol Heart Circ Physiol. 1997; 273(6): H2876-H2883.
- 67Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol Heart Circ Physiol. 1997; 272(1): H148-H158.
- 68Yokoe S, Asahi M, Takeda T, et al. Inhibition of phospholamban phosphorylation by O-GlcNAcylation: implications for diabetic cardiomyopathy. Glycobiology. 2010; 20(10): 1217-1226.
- 69Fricovsky ES, Suarez J, Ihm S-H, et al. Excess protein O-GlcNAcylation and the progression of diabetic cardiomyopathy. Am J Physiol Regul Integr Comp Physiol. 2012; 303(7): R689-R699.
- 70Bers DM, Grandi E. Calcium/calmodulin-dependent kinase II regulation of cardiac ion channels. J Cardiovasc Pharmacol. 2009; 54(3): 180-187.
- 71Lu S, Liao Z, Lu X, et al. Hyperglycemia acutely increases cytosolic reactive oxygen species via O-linked GlcNAcylation and CaMKII activation in mouse ventricular myocytes. Circ Res. 2020; 126(10): e80-e96.
- 72Jackson SP, Tjian R. O-glycosylation of eukaryotic transcription factors: implications for mechanisms of transcriptional regulation. Cell. 1988; 55(1): 125-133.
- 73Wankerl M, Boheler KR, Fiszman MY, Schwartz K. Molecular cloning and analysis of the human cardiac sarco(endo)plasmic reticulum Ca(2+)-ATPase (SERCA2) gene promoter. J Mol Cell Cardiol. 1996; 28(10): 2139-2150.
- 74Di Lisi R, Millino C, Calabria E, Altruda F, Schiaffino S, Ausoni S. Combinatorial cis-acting elements control tissue-specific activation of the cardiac troponin I gene in vitro and in vivo. J Biol Chem. 1998; 273(39): 25371-25380.
- 75Santalucia T, Boheler KR, Brand NJ, et al. Factors involved in GLUT-1 glucose transporter gene transcription in cardiac muscle. J Biol Chem. 1999; 274(25): 17626-17634.
- 76Zhuang Y, Wendt C, Gick G. Regulation of Na, K-ATPase beta 1 subunit gene transcription by low external potassium in cardiac myocytes. Role of Sp1 AND Sp3. J Biol Chem. 2000; 275(31): 24173-24184.
- 77Bennett CE, Johnsen VL, Shearer J, Belke DD. Exercise training mitigates aberrant cardiac protein O-GlcNAcylation in streptozotocin-induced diabetic mice. Life Sci. 2013; 92(11): 657-663.
- 78Belke DD. Swim-exercised mice show a decreased level of protein O-GlcNAcylation and expression of O-GlcNAc transferase in heart. J Appl Physiol. 2011; 111(1): 157-162.
- 79Ramirez-Correa GA, Jin W, Wang Z, et al. O-linked GlcNAc modification of cardiac myofilament proteins: a novel regulator of myocardial contractile function. Circ Res. 2008; 103(12): 1354-1358.
- 80Labeit S, Kolmerer B, Linke WA. The giant protein titin. Circ Res. 1997; 80(2): 290-294.
- 81Feher J. 3.5 - Contractile mechanisms in skeletal muscle. In: J Feher, ed. Quantitative human physiology. Boston, MA: Academic Press; 2012: 249-258.
10.1016/B978-0-12-382163-8.00028-1 Google Scholar
- 82Chandra M, Dong W-J, Pan B-S, Cheung HC, Solaro RJ. Effects of protein kinase A phosphorylation on signaling between cardiac troponin I and the N-terminal domain of cardiac troponin C. Biochemistry. 1997; 36(43): 13305-13311.
- 83Van Der Velden J, Narolska NA, Lamberts RR, et al. Functional effects of protein kinase C-mediated myofilament phosphorylation in human myocardium. Cardiovasc Res. 2006; 69(4): 876-887.
- 84Stienen GJM, van der Velden J, de Jong JW, Burton PBJ, Owen VJ. Effect of protein kinase A on calcium sensitivity of force and its sarcomere length dependence in human cardiomyocytes. Cardiovasc Res. 2000; 46(3): 487-495.
- 85Gelinas R, Mailleux F, Dontaine J, et al. AMPK activation counteracts cardiac hypertrophy by reducing O-GlcNAcylation. Nat Commun. 2018; 9(1): 374.
- 86Dubois-Deruy E, Belliard A, Mulder P, et al. Interplay between troponin T phosphorylation and O-N-acetylglucosaminylation in ischaemic heart failure. Cardiovasc Res. 2015; 107(1): 56-65.
- 87Xing D, Feng W, Nöt LG, et al. Increased protein O-GlcNAc modification inhibits inflammatory and neointimal responses to acute endoluminal arterial injury. Am J Physiol Heart Circ Physiol. 2008; 295(1): H335-H342.
- 88Xing D, Feng W, Hage F, Paterson Andrew J, Chatham John C, Oparil S. Vascular smooth muscle cell-selective O-GlcNAcylation protects arteries against acute injury. Circulation. 2013; 128: A13061.
- 89Xing D, Gong K, Feng W, et al. O-GlcNAc modification of NFκB p65 inhibits TNF-α-induced inflammatory mediator expression in rat aortic smooth muscle cells. PLoS One. 2011; 6(8):e24021.
- 90Hilgers RHP, Xing D, Gong K, Chen Y-F, Chatham JC, Oparil S. Acute O-GlcNAcylation prevents inflammation-induced vascular dysfunction. Am J Physiol Heart Circ Physiol. 2012; 303(5): H513-H522.
- 91Silva JF, Olivon VC, Mestriner FLAC, et al. Acute increase in O-GlcNAc improves survival in mice with LPS-induced systemic inflammatory response syndrome. Front Physiol. 2020; 10:1614.
- 92Yao D, Xu L, Xu O, et al. O-Linked β-N-acetylglucosamine modification of A20 enhances the inhibition of NF-κB (nuclear factor-κB) activation and elicits vascular protection after acute endoluminal arterial injury. Arterioscler Thromb Vasc Biol. 2018; 38(6): 1309-1320.
- 93Lilly B. We have contact: endothelial cell-smooth muscle cell interactions. Physiology. 2014; 29(4): 234-241.
- 94Federici M, Menghini R, Mauriello A, et al. Insulin-dependent activation of endothelial nitric oxide synthase is impaired by O-linked glycosylation modification of signaling proteins in human coronary endothelial cells. Circulation. 2002; 106(4): 466-472.
- 95Makino A, Dai A, Han Y, et al. O-GlcNAcase overexpression reverses coronary endothelial cell dysfunction in type 1 diabetic mice. Am J Physiol Cell Physiol. 2015; 309(9): C593-C599.
- 96Matthys KE, Bult H. Nitric oxide function in atherosclerosis. Mediators Inflamm. 1997; 6(1): 3-21.
- 97Chen K, Pittman RN, Popel AS. Nitric oxide in the vasculature: where does it come from and where does it go? A quantitative perspective. Antioxid Redox Signal. 2008; 10(7): 1185-1198.
- 98Förstermann U, Münzel T. Endothelial nitric oxide synthase in vascular disease. Circulation. 2006; 113(13): 1708-1714.
- 99Du XL, Edelstein D, Dimmeler S, Ju Q, Sui C, Brownlee M. Hyperglycemia inhibits endothelial nitric oxide synthase activity by posttranslational modification at the Akt site. J Clin Invest. 2001; 108(9): 1341-1348.
- 100Lima VV, Giachini FR, Choi H, et al. Impaired vasodilator activity in deoxycorticosterone acetate-salt hypertension is associated with increased protein O-GlcNAcylation. Hypertension. 2009; 53(2): 166-174.
- 101Everhart JE, Pettitt DJ, Knowler WC, Rose FA, Bennett PH. Medial arterial calcification and its association with mortality and complications of diabetes. Diabetologia. 1988; 31(1): 16-23.
- 102Meigs JB, Larson MG, D’Agostino RB, et al. Coronary artery calcification in type 2 diabetes and insulin resistance. Diabetes Care. 2002; 25(8): 1313-1319.
- 103Lanzer P, Boehm M, Sorribas V, et al. Medial vascular calcification revisited: review and perspectives. Eur Heart J. 2014; 35(23): 1515-1525.
- 104Akimoto Y, Kreppel LK, Hirano H, Hart GW. Hyperglycemia and the O-GlcNAc transferase in rat aortic smooth muscle cells: elevated expression and altered patterns of O-GlcNAcylation. Arch Biochem Biophys. 2001; 389(2): 166-175.
- 105Ganguly R, Sahu S, Chavez RJ, Raman P. Trivalent chromium inhibits TSP-1 expression, proliferation, and O-GlcNAc signaling in vascular smooth muscle cells in response to high glucose in vitro. Am J Physiol Cell Physiol. 2014; 308(2): C111-C122.
- 106Souza-Silva L, Alves-Lopes R, Silva Miguez J, et al. Glycosylation with O-linked β-N-acetylglucosamine induces vascular dysfunction via production of superoxide anion/reactive oxygen species. Can J Physiol Pharmacol. 2017; 96(3): 232-240.
- 107Vigetti D, Deleonibus S, Moretto P, et al. Role of UDP-N-acetylglucosamine (GlcNAc) and O-GlcNAcylation of hyaluronan synthase 2 in the control of chondroitin sulfate and hyaluronan synthesis. J Biol Chem. 2012; 287(42): 35544-35555.
- 108Heath JM, Sun Y, Yuan K, et al. Activation of AKT by O-linked N-acetylglucosamine induces vascular calcification in diabetes mellitus. Circ Res. 2014; 114(7): 1094-1102.
- 109Lima VV, Lobato NS, Filgueira FP, Webb RC, Tostes RC, Giachini FR. Vascular O-GlcNAcylation augments reactivity to constrictor stimuli by prolonging phosphorylated levels of the myosin light chain. Braz J Med Biol Res. 2014; 47(10): 826-833.
- 110Lima VV, Giachini FR, Carneiro FS, et al. O-GlcNAcylation contributes to the vascular effects of ET-1 via activation of the RhoA/Rho-kinase pathway. Cardiovasc Res. 2011; 89(3): 614-622.
- 111Kim DH, Seok YM, Kim IK, Lee IK, Jeong SY, Jeoung NH. Glucosamine increases vascular contraction through activation of RhoA/Rho kinase pathway in isolated rat aorta. BMB Rep. 2011; 44(6): 415-420.
- 112Stenina OI, Krukovets I, Wang K, et al. Increased expression of thrombospondin-1 in vessel wall of diabetic Zucker rat. Circulation. 2003; 107(25): 3209-3215.
- 113Choi K-Y, Kim D-B, Kim M-J, et al. Higher plasma thrombospondin-1 levels in patients with coronary artery disease and diabetes mellitus. Korean Circ J. 2012; 42(2): 100-106.
- 114Goldberg HJ, Whiteside CI, Hart GW, Fantus IG. Posttranslational, reversible O-glycosylation is stimulated by high glucose and mediates plasminogen activator inhibitor-1 gene expression and Sp1 transcriptional activity in glomerular mesangial cells. Endocrinology. 2006; 147(1): 222-231.
- 115Regan TJ, Lyons MM, Ahmed SS, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest. 1977; 60(4): 885-899.
- 116Aronson D. Cross-linking of glycated collagen in the pathogenesis of arterial and myocardial stiffening of aging and diabetes. J Hypertens. 2003; 21(1): 3-12.
- 117Fowlkes V, Clark J, Fix C, et al. Type II diabetes promotes a myofibroblast phenotype in cardiac fibroblasts. Life Sci. 2013; 92(11): 669-676.
- 118Shamhart PE, Luther DJ, Hodson BR, Koshy JC, Ohanyan V, Meszaros JG. Impact of type 1 diabetes on cardiac fibroblast activation: enhanced cell cycle progression and reduced myofibroblast content in diabetic myocardium. Am J Physiol Endocrinol Metab. 2009; 297(5): E1147-E1153.
- 119Burr SD, Stewart JA. Extracellular matrix components isolated from diabetic mice alter cardiac fibroblast function through the AGE/RAGE signaling cascade. Life Sci. 2020; 250:117569.
- 120Kanekar S, Hirozanne T, Terracio L, Borg TK. Cardiac fibroblasts form and function. Cardiovasc Pathol. 1998; 7(3): 127-133.
- 121Baudino TA, Carver W, Giles W, Borg TK. Cardiac fibroblasts: friend or foe? Am J Physiol Heart Circ Physiol. 2006; 291(3): H1015-H1026.
- 122Shamhart PE, Luther DJ, Adapala RK, et al. Hyperglycemia enhances function and differentiation of adult rat cardiac fibroblasts. Can J Physiol Pharmacol. 2014; 92(7): 598-604.
- 123Aguilar H, Fricovsky E, Ihm S, et al. Role for high-glucose-induced protein O-GlcNAcylation in stimulating cardiac fibroblast collagen synthesis. Am J Physiol Cell Physiol. 2014; 306(9): C794-C804.
